Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first-year results from a randomized clinical trial.

Context: Short stature in children may be associated with low IGF-I despite normal stimulated GH levels and without other causes.

Objective: Our objective was to assess the safety and efficacy of recombinant human IGF-I (rhIGF-I) in short children with low IGF-I levels.

Design: This was a 1-yr, randomized, open-label trial (MS301).